## Giada Sebastiani

## List of Publications by Citations

Source: https://exaly.com/author-pdf/8452538/giada-sebastiani-publications-by-citations.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

113<br/>papers4,207<br/>citations36<br/>h-index64<br/>g-index121<br/>ext. papers5,344<br/>ext. citations4.9<br/>avg, IF5.64<br/>L-index

#	Paper	IF	Citations
113	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. <i>Hepatology</i> , <b>2017</b> , 65, 1557-1565	11.2	796
112	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , <b>2020</b> , 158, 1611-1625.e12	13.3	234
111	Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 686-93	13.4	222
110	Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 3682-94	5.6	197
109	Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2010</b> , 52, 191-8	13.4	158
108	SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. <i>Hepatology</i> , <b>2009</b> , 49, 1821-7	11.2	132
107	Chronic hepatitis C and liver fibrosis. World Journal of Gastroenterology, 2014, 20, 11033-53	5.6	130
106	Cloning and characterization of the murine toll-like receptor 5 (Tlr5) gene: sequence and mRNA expression studies in Salmonella-susceptible MOLF/Ei mice. <i>Genomics</i> , <b>2000</b> , 64, 230-40	4.3	112
105	Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. <i>World Journal of Gastroenterology</i> , <b>2007</b> , 13, 525-31	5.6	111
104	Liver fibrosis: Review of current imaging and MRI quantification techniques. <i>Journal of Magnetic Resonance Imaging</i> , <b>2017</b> , 45, 1276-1295	5.6	110
103	The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 1202-16	6.1	94
102	Prediction of oesophageal varices in hepatic cirrhosis by simple serum non-invasive markers: Results of a multicenter, large-scale study. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 630-8	13.4	92
101	A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. <i>Hepatology</i> , <b>2009</b> , 50, 1038-44	11.2	80
100	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 878-885	13.4	75
99	Pharmacological Targeting of the Hepcidin/Ferroportin Axis. Frontiers in Pharmacology, <b>2016</b> , 7, 160	5.6	73
98	Mapping of genetic modulators of natural resistance to infection with Salmonella typhimurium in wild-derived mice. <i>Genomics</i> , <b>1998</b> , 47, 180-6	4.3	68
97	Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 2190-203	5.6	62

## (2018-2020)

96	Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Reports, 2020, 2, 100067	10.3	54
95	Conditional disruption of mouse HFE2 gene: maintenance of systemic iron homeostasis requires hepatic but not skeletal muscle hemojuvelin. <i>Hepatology</i> , <b>2011</b> , 54, 1800-7	11.2	47
94	Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 1937-44	4.5	47
93	An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 807-15	13.4	46
92	Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. <i>Aids</i> , <b>2016</b> , 30, 2635-2643	3.5	46
91	Prospective comparison of transient, point shear wave, and magnetic resonance elastography for staging liver fibrosis. <i>European Radiology</i> , <b>2019</b> , 29, 6477-6488	8	46
90	Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0128774	3.7	46
89	Systematic review: Preventive and therapeutic applications of metformin in liver disease. <i>World Journal of Hepatology</i> , <b>2015</b> , 7, 1652-9	3.4	46
88	2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. <i>HIV Medicine</i> , <b>2020</b> , 21, 617-624	2.7	46
87	Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 801-808	13.4	44
86	Disorders associated with systemic or local iron overload: from pathophysiology to clinical practice. <i>Metallomics</i> , <b>2011</b> , 3, 971-86	4.5	44
85			
	Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 83-7	13.4	43
84		13.4	43
84	therapy predicts post-treatment relapse. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 83-7  Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From		
	therapy predicts post-treatment relapse. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 83-7  Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 1160-1167  Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal	11.6	43
83	therapy predicts post-treatment relapse. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 83-7  Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 1160-1167  Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. <i>Journal of Viral Hepatitis</i> , <b>2008</b> , 15, 212-8  Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C. <i>Journal of Viral</i>	11.6 3.4	43
83	therapy predicts post-treatment relapse. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 83-7  Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 1160-1167  Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. <i>Journal of Viral Hepatitis</i> , <b>2008</b> , 15, 212-8  Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , <b>2006</b> , 13, 199-205  Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article.	11.6 3.4 3.4	43 40 40

78	Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 92-104	6.1	36
77	Differences in activation of mouse hepcidin by dietary iron and parenterally administered iron dextran: compartmentalization is critical for iron sensing. <i>Journal of Molecular Medicine</i> , <b>2013</b> , 91, 95-10	)2 <sup>5.5</sup>	35
76	How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C?. <i>Journal of Viral Hepatitis</i> , <b>2012</b> , 19 Suppl 1, 18-32	3.4	34
75	Hepatic iron overload is common in chronic hepatitis B and is more severe in patients coinfected with hepatitis D virus. <i>Journal of Viral Hepatitis</i> , <b>2012</b> , 19, e170-6	3.4	33
74	HFE gene in primary and secondary hepatic iron overload. <i>World Journal of Gastroenterology</i> , <b>2007</b> , 13, 4673-89	5.6	33
73	Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2014</b> , 28, 23-30	2.8	31
72	Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 124-133	4.5	30
71	Iron-dependent regulation of hepcidin in Hjv-/- mice: evidence that hemojuvelin is dispensable for sensing body iron levels. <i>PLoS ONE</i> , <b>2014</b> , 9, e85530	3.7	28
70	Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrent fibrosis after liver transplantation: A meta-analysis. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185192	3.7	27
69	Accelerated CCl4-induced liver fibrosis in Hjv-/- mice, associated with an oxidative burst and precocious profibrogenic gene expression. <i>PLoS ONE</i> , <b>2011</b> , 6, e25138	3.7	21
68	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 806-815.e5	6.9	21
67	Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy. <i>Antiviral Research</i> , <b>2012</b> , 96, 422-9	10.8	20
66	Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection. <i>PLoS ONE</i> , <b>2018</b> , 13, e0191985	3.7	19
65	Incidence and predictors of hepatic steatosis and fibrosis by serum biomarkers in a large cohort of human immunodeficiency virus mono-infected patients. <i>Open Forum Infectious Diseases</i> , <b>2015</b> , 2, ofv01.	5 <sup>1</sup>	17
64	Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study. <i>CMAJ Open</i> , <b>2020</b> , 8, E429-E436	2.5	16
63	Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2011</b> , 49, 13-32	5.9	16
62	Serum fibrosis biomarkers predict death and graft loss in liver transplantation recipients. <i>Liver Transplantation</i> , <b>2015</b> , 21, 1383-94	4.5	15
61	AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 860-8	3.3	14

## (2021-2012)

60	Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening. <i>Hepatology</i> , <b>2012</b> , 56, 455-63	11.2	13
59	Clinical significance of elevated liver transaminases in HIV-infected patients. <i>Aids</i> , <b>2019</b> , 33, 1267-1282	3.5	13
58	Using the barriers and facilitators to linkage to HIV care to inform hepatitis C virus (HCV) linkage to care strategies for people released from prison: Findings from a systematic review. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 205-220	3.4	12
57	Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients. <i>Aids</i> , <b>2020</b> , 34, 237-244	3.5	12
56	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 12-19	3.4	12
55	Noninvasive Markers of Portal Hypertension Detect Decompensation in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 3017-3025.e6	6.9	11
54	New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. <i>Hepatology</i> , <b>2020</b> , 71, 183	1 <u>r18</u> 4	4 10
53	Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, e694-e701	11.6	9
52	Transient elastography is an unreliable marker of liver fibrosis in patients with portal vein thrombosis. <i>Hepatology</i> , <b>2018</b> , 68, 783-785	11.2	9
51	The hepatitis C virus cascade of care in a Quebec provincial prison: a retrospective cohort study. <i>CMAJ Open</i> , <b>2019</b> , 7, E674-E679	2.5	8
50	Occult cirrhosis diagnosed by transient elastography is a frequent and under-monitored clinical entity. <i>Liver International</i> , <b>2015</b> , 35, 2285-93	7.9	7
49	Fatty liver in H63D homozygotes with hyperferritinemia. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 1788-92	5.6	7
48	Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 2810-2817	11.6	7
47	Liver-related Events in Human Immunodeficiency Virus-infected Persons With Occult Cirrhosis. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 1422-1430	11.6	7
46	Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome. <i>World Journal of Gastroenterology</i> , <b>2020</b> , 26, 7046-7060	5.6	6
45	NASH in HIV. Current HIV/AIDS Reports, 2020, 17, 601-614	5.9	6
44	Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients. <i>HIV Medicine</i> , <b>2020</b> , 21, 96-108	2.7	6
43	Intravoxel incoherent motion diffusion-weighted MRI for theEtharacterization of inflammation in chronic liver disease. European Radiology, 2021, 31, 1347-1358	8	6

42	Implementing non-invasive markers for liver fibrosis in clinical practice. <i>Journal of Hepatology</i> , <b>2008</b> , 48, 880-1; author reply 881-3	13.4	5
41	Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Monoinfection. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e2184-e2193	11.6	5
40	Distinct Hepatitis B and HIV co-infected populations in Canada. Journal of Viral Hepatitis, 2021, 28, 517-	53.7	5
39	Non-alcoholic fatty liver disease in premenopausal women with polycystic ovary syndrome: A systematic review and meta-analysis. <i>JGH Open</i> , <b>2021</b> , 5, 434-445	1.8	5
38	Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 222, 787-79	97	4
37	Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV. <i>Aids</i> , <b>2020</b> , 34, 1915-1921	3.5	4
36	MRI cine-tagging of cardiac-induced motion for noninvasive staging of liver fibrosis. <i>Journal of Magnetic Resonance Imaging</i> , <b>2020</b> , 51, 1570-1580	5.6	4
35	Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2013</b> , 25, 1385-95	2.2	3
34	HIV, Elevated Transaminases, Fatty Liver: The Perfect Storm?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 81, e23-e25	3.1	3
33	Clinical trial: comparison of weekly once versus twice half-dose weekly administration of pegylated interferon alpha 2b in combination with ribavirin for the treatment of HCV-1 positive patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 26, 1077-82	6.1	2
32	Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis <i>Alimentary Pharmacology and Therapeutics</i> , <b>2022</b> ,	6.1	2
31	Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 942-950	3.4	2
30	Hepatic steatosis, hepatitis C, and human immunodeficiency viruses: A complex interplay. Hepatology, <b>2017</b> , 66, 673-674	11.2	1
29	Reply to "Transient Elastography in IBD Patients". <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, e95	4.5	1
28	A199 SCREENING FOR NONALCOHOLIC FATTY LIVER DISEASE BY TRANSIENT ELASTOGRAPHY WITH CONTROLLED ATTENUATION PARAMETER IN UNSELECTED PATIENTS WITH INFLAMMATORY BOWEL DISEASE. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2018</b> , 1, 347	0.5 -348	1
27	Noninvasive diagnosis of liver fibrosis: The importance of being reimbursed. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2015</b> , 29, 219-20	2.8	1
26	A care coordination program to optimize management of cirrhosis: real-life applicability and feasibility in the context of the Canadian health care system. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2014</b> , 28, 221-2	2.8	1
25	Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. <i>Journal of Viral Hepatitis</i> , <b>2008</b> , 15, 474-474	3.4	1

24	Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome Open Forum Infectious Diseases, <b>2022</b> , 9, ofac003	1	1
23	FIB-4 Improves LSM-Based Prediction of Complications in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	1
22	Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 1959-1972	5.6	1
21	Nonalcoholic Fatty Liver Disease in Human Immunodeficiency Virus: The (Not So) New Kid on the Block?. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 243-244	11.6	1
20	A190 REGRESSION OF LIVER FIBROSIS AFTER SUCCESSFUL ALL ORAL ANTIVIRAL THERAPY IN HCV CIRRHOSIS: A PILOT STUDY EMPLOYING TRANSIENT ELASTOGRAPHY AND CONTROLLED ATTENUATION PARAMETER (CAP). <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2018</b> , 1, 331	0.5 - <b>331</b>	1
19	Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 35, 107978	3.2	1
18	Development and validation of an ensemble machine learning framework for detection of all-cause advanced hepatic fibrosis: a retrospective cohort study <i>The Lancet Digital Health</i> , <b>2022</b> , 4, e188-e199	14.4	1
17	Incidence and Predictors of Advanced Liver Fibrosis by a Validated Serum Biomarker in Liver Transplant Recipients. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2017</b> , 2017, 4381864	2.8	O
16	Quantitative ultrasound, elastography, and machine learning for assessment of steatosis, inflammation, and fibrosis in chronic liver disease <i>PLoS ONE</i> , <b>2022</b> , 17, e0262291	3.7	О
15	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). <i>Canadian Liver Journal</i> , <b>2022</b> , 5, 61-90	0.3	O
14	The 8th Canadian Symposium on Hepatitis C virus: Improving diagnosis and linkage to care Canadian Liver Journal, <b>2020</b> , 3, 3-14	0.3	О
13	Inference about time-dependent prognostic accuracy measures in the presence of competing risks. <i>BMC Medical Research Methodology</i> , <b>2020</b> , 20, 219	4.7	0
12	A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 66, 4046-40	o <del>\$</del> 7	О
11	Current Considerations for Clinical Management and Care of People with HIV: Findings from the 11th Annual International HIV and Aging Workshop. <i>AIDS Research and Human Retroviruses</i> , <b>2021</b> , 37, 807-820	1.6	O
10	Non-alcoholic steatohepatitis in liver transplant recipients diagnosed by serum cytokeratin 18 and transient elastography: A prospective study <i>World Journal of Hepatology</i> , <b>2021</b> , 13, 2179-2191	3.4	О
9	Non-invasive algorithms for liver fibrosis: authors leply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 311-313	6.1	
8	Fibrosis Assessment via Liver Stiffness Measurements: How Many Patients Are Spared from a Liver Biopsy? <b>2020</b> , 563-588		
7	Optimizing patients with non-alcoholic fatty liver disease pre-transplant. <i>Canadian Liver Journal</i> , <b>2020</b> , 3, 237-250	0.3	

6	Reply to Giannini et al. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, 1863-1864	11.6
5	Reply to: "Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease". <i>Journal of Hepatology</i> , <b>2018</b> , 69, 1203-1204	13.4
4	Acute liver failure in ruptured sinus of Valsalva aneurysm. Canadian Liver Journal, e20210012	0.3
3	A110 FEASIBILITY OF EUS-GUIDED PORTAL PRESSURE GRADIENT MEASUREMENT WITHOUT DEEP SEDATION: A PATH TO ACCURATE PORTAL PRESSURE DETERMINATION. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2022</b> , 5, 127-128	0.5
2	A220 THE IMPACT OF DIABETES AND AGE ON PERFORMANCE OF NON-INVASIVE SERUM-BASED TESTS FOR PREDICTION OF ADVANCED FIBROSIS IN BIOPSY-PROVEN NAFLD. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2022</b> , 5, 109-110	0.5
1	Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway <i>Lancet HIV,the</i> , <b>2022</b> , 9 Suppl 1, S4	7.8